Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Baselga, José; Bradbury, Ian; Eidtmann, Holger; Di Cosimo, Serena; de Azambuja, Evandro; Aura, Claudia; Gomez, Henry; Dinh, Phuong; Fauria, Karine; van Dooren, Veerle; Aktan, Gursel; Goldhirsch, Aron; Chang, Tsai-Wang; Horváth, Zsolt; Coccia-Portugal, Maria; Domont, Julien; Tseng, Ling-Min; Kunz, Georg; Sohn, Joo Hyuk; Semiglazov, Vladimir; Lerzo, Guillermo; Palacova, Marketa; Probachai, Volodymyr; Pusztai, Lajos; Untch, Michael; Gelber, Richard; Piccart-Gebhart, Martine; NeoALTTO Study Team

doi:doi/10.1016/S0140-6736(11)61847-3

Recherche avancée | Historique de recherche Mon DI-fusion | À propos de DI-fusion | Contact |

Citer

Article révisé par les pairs

Résumé :

The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than single-agent therapy.

Documents en relation

DI-fusion

Adjuvant CDK4/6 Inhibitors for Early Breast Cancer: How to Choose Wisely?
par Agostinetto, Elisa , Arecco, Luca , de Azambuja, Evandro
Publication 2024-03
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer
par Agostinetto, Elisa , de Azambuja, Evandro , Lambertini, Matteo Md Phd M.
Publication 2023-12
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
par Rediti, Mattia , Fernandez-Martinez, Aranzazu , Venet, David , Rothé, Françoise , Hoadley, Katherine A , Parker, Joel S , Singh, Baljit , Campbell, Jordan D , Ballman, Karla V , Hillman, David W , Winer, Eric P , El-Abed, Sarra , Piccart, Martine , Di Cosimo, Serena , Symmans, William Fraser , Krop, Ian , Salgado, Roberto , Loi, Sherene , Pusztai, Lajos , Perou, Charles M , Carey, Lisa A , Sotiriou, Christos
Publication 2023-11
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer
par Lambertini, Matteo , Ceppi, Marcello , Anderson, Richard A , Cameron, David A , Bruzzone, Marco , Franzoi, Maria Alice , Massarotti, Claudia , El-Abed, Sarra , Wang, Yingbo , Lecocq, Christophe , Nuciforo, Paolo , Rolyance, Rebecca , Pusztai, Lajos , Sohn, Joohyuk , Latocca, Maria Maddalena , Arecco, Luca , Pistilli, Barbara , Ruddy, Kathryn J , Ballestrero, Alberto , Del Mastro, Lucia , Peccatori, Fedro Alessandro , Partridge, Ann H , Saura, Cristina , Untch, Michael , Piccart, Martine , Di Cosimo, Serena , de Azambuja, Evandro , Demeestere, Isabelle
Publication 2023-01-23
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)
par Caballero, Carmela , Irrthum, Alexandre , Goulioti, Theodora , Cameron, David A , Norton, Larry , Piccart-Gebhart, Martine
Publication 2023-12

Référencement	Visibilité	Pérennité	Facilité
Les publications encodées constituent la bibliographie académique de l'Université.	Les documents déposés sont indexés par les moteurs de recherche (Google Scholar,…).	Les documents déposés en open-access sont archivés au sein du réseau de préservation SAFE-PLN (www.safepln.org).	Les listes de publications sont compatibles avec le CV-ULB, le FNRS et accessibles sur le web.